CatalystCorporate

SAM ALTMAN'S LONGEVITY STARTUP IS UPPING THE DOSE IN AN ALZHEIMER'S DRUG TRIAL AFTER A LACKLUSTER FIRST ROUND - BUSINSIDER

Alzheimer's trial dose increase signals catalyst after lackluster first round.

What changed

Alzheimer's trial dose increase signals catalyst after lackluster first round.

Why it matters

Alzheimer's trial dose increase signals catalyst after lackluster first round. — impact context not separately stored; see What changed.

Sources